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RESEARCH ARTICLE
Robust Intensity Modulated Proton Therapy
(IMPT) Increases Estimated Clinical Benefit
in Head and Neck Cancer Patients
Lisanne V. van Dijk1,2*, Roel J. H. M. Steenbakkers1, Bennie ten Haken2, Hans Paul van
der Laan1, Aart A. van ‘t Veld1, Johannes A. Langendijk1, Erik W. Korevaar1
1 Department of Radiation Oncology, University of Groningen, University Medical Center Groningen,
Groningen, The Netherlands, 2 Institute for Biomedical Technology and Technical Medicine (MIRA),




To compare the clinical benefit of robust optimized Intensity Modulated Proton Therapy
(minimax IMPT) with current photon Intensity Modulated Radiation Therapy (IMRT) and
PTV-based IMPT for head and neck cancer (HNC) patients. The clinical benefit is quantified
in terms of both Normal Tissue Complication Probability (NTCP) and target coverage in the
case of setup and range errors.
Methods and Materials
For 10 HNC patients, PTV-based IMRT (7 fields), minimax and PTV-based IMPT (2, 3, 4, 5
and 7 fields) plans were tested on robustness. Robust optimized plans differed from PTV-
based plans in that they target the CTV and penalize possible error scenarios, instead of
using the static isotropic CTV-PTV margin. Perturbed dose distributions of all plans were
acquired by simulating in total 8060 setup (±3.5 mm) and range error (±3%) combinations.
NTCP models for xerostomia and dysphagia were used to predict the clinical benefit of
IMPT versus IMRT.
Results
The robustness criterion was met in the IMRT and minimax IMPT plans in all error scenar-
ios, but this was only the case in 1 of 40 PTV-based IMPT plans. Seven (out of 10) patients
had relatively large NTCP reductions in minimax IMPT plans compared to IMRT. For these
patients, xerostomia and dysphagia NTCP values were reduced by 17.0% (95% CI; 13.0–
21.1) and 8.1% (95% CI; 4.9–11.2) on average with minimax IMPT. Increasing the number
of fields did not contribute to plan robustness, but improved organ sparing.
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Conclusions
The estimated clinical benefit in terms of NTCP of robust optimized (minimax) IMPT is
greater than that of IMRT and PTV-based IMPT in HNC patients. Furthermore, the target
coverage of minimax IMPT plans in the presence of errors was comparable to IMRT plans.
Introduction
In Head and Neck Cancer (HNC) patients, radiation-induced side effects, in particular xerosto-
mia and dysphagia, have a major impact on quality of life [1–3]. In the last decades, Intensity
Modulated Proton Therapy (IMPT) has developed as a treatment modality to reduce these side
effects in HNC patients [4–8]. Unfortunately, IMPT can be more sensitivity to uncertainties in
patient setup, CT values and patient anatomy than intensity modulated radiotherapy (IMRT)
as radiologic path length changes result in displacements of the steep Bragg peak fall-off. In
particular, range errors, which arise from inaccuracies in the planning CT and the CT Houns-
field units-to-stopping power calibration curve, are an issue in proton therapy [9–11]. Cur-
rently, in both IMRT and IMPT, these uncertainties are commonly taken into account by
expanding the clinical target volume (CTV) to the planning target volume (PTV) to ensure
adequate dose coverage of the CTV [12,13]. However, the physical properties of protons can
conflict with this traditional CTV-PTV concept, as errors can result in centralized target vol-
ume under-dosage, ultimately risking tumor recurrence [11,14–19]. Therefore, proton therapy
requires a different approach to achieve robustness, which refers to the correspondence of
planned and actual dose distributions in presence of errors and unanticipated changes. Park
et al. [20] showed that a field-specific PTV was beneficial for single field uniform dose (SFUD),
where each field delivers uniform dose to the target volume. However, IMPT requires a more
complex integration to achieve robustness.
Including robustness in the optimization has been proposed as strategy by several authors
to reduce the impact of potential errors [14,15,21]. Fredriksson et al. [22] has developed a
worst case scenario optimization (i.e. minimax optimization), that penalizes the perturbed
dose distributions that are the most unfavorable by minimization of the worst objective func-
tion value that corresponds to one scenario. Dealing with worst case physically realizable dose
distributions, makes this approach less conservative [10] and computationally more demand-
ing than other robust optimization implementations [14].
Multiple studies have shown the potential benefits of IMPT for HNC patients by comparing
proton therapy with photon modalities [4,5]. However, these comparisons were potentially not
fair, because the used IMPT plans were PTV-based and may, therefore, lack robustness. In the
head and neck regions the presence of multiple nearby Organs At Risk (OARs) that are prefera-
bly spared as much as possible makes HNC plans complex. It is therefore especially important
in these patients to incorporate robustness in the optimization process [23]. However, just as
important is the evaluation of the robustness of these plans by examining the target coverage in
presence of setup and range errors. No anatomic deformations were included in our study.
Our study is the first to evaluate IMRT, PTV-based IMPT and robust optimized IMPT
plans not only in terms of dose to OARs and estimated clinical benefit in terms of normal tissue
complication probabilities (NTCP), but also on robustness in terms of target coverage and
NTCP. Furthermore, all treatment plans were generated using the same treatment planning
system. This allows comparison of the different modalities without introducing biases related
to the use of different planning systems [19]. Since the number of fields in robust planning
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might influence the dose to OARs [18] or the robustness of the IMPT plans [11,14,17], this
aspect was also included in our study.
Methods and Materials
Patients and inclusion criteria
For this study, 10 HNC patients with varying tumor sites, extensions and regional lymph node
status were included (Table 1). All patients were treated bilaterally with parotid and swallowing
sparing IMRT [24].
Ethics Statement
All patients provided written informed consent before starting therapy that their data could be
used within the department’s research program. Some of the authors were directly involved in
treating patients and had access to identifying patient information. All data was anonymized
by one of the authors (LD) and collected as part of a prospective data registration program
within the framework of routine clinical practice. The Dutch Medical Research Involving
Human Subjects Act is not applicable to data collection as part of routine clinical practice and
therefore, the hospital ethics committee granted us a waiver from needing ethical approval for
the conduct of studies based on these data. The treatment planning reported in this retrospec-
tive study was not used for actual patient treatment. All patients received the standard clinical
practice of treatment with IMRT.
IMRT and IMPT plan specifics
The clinical 7-field IMRT plans were optimized in the RaySearch treatment planning system
(RayStation version 3.99) for 6 MV photon beams of an Elekta linear accelerator equipped
with an MLC with 10 mm leaf width. All IMRT treatments applied a simultaneous integrated
boost (SIB).
IMPT plans were constructed using 4 different field configurations (Table 2) in the Ray-
Search treatment planning system. The initial beam energy ranged between 70 and 230 MeV
for an IBA dedicated gantry with a spot size in air of 3 mm at highest energy (one sigma).
Range shifters of 40 mm water equivalent thickness were available.
Table 1. Patient characteristics.
Tumor location Staging Nodal Levels left and right CTV70 volume (cm
3)
1 Glottis larynx T3N0 II-VI II-VI 15
2 Oropharynx T3N2b Ib-V* Ib-IV* 195
3 Oropharynx T4N2c Ib-V* Ib-V* 157
4 Nasopharynx T4N1 Ib-V* II-III 154
5 Nasopharynx T2N3 Ib-V* Ib-V* 326
6 Supraglottis Larynx T3 N2c Ib-V Ib-V 100
7 Oropharynx T3 N0 II-IV Ib-IV 80
8 Oropharynx T2N2b II-IV I-V* 96
9 Oropharynx T1N0 II-IV II-IV 22
10 Oropharynx T2N0 II-IV II-IV 43
*retrostyloid, retropharyngeal
doi:10.1371/journal.pone.0152477.t001
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PTV-based IMRT plans. In the clinical plans of the patients included in this study the
CTV to PTV margin was 5mm. With on-line cone beam CT setup correction tighter margins
are feasible so for this study the criterion was used that plans needed to be robust against setup
errors of 3.5 mm and PTVs were reduced accordingly [25]. Prescribed doses of 70 Gy and
54.25 Gy were conformed to the targets PTV70 and PTV54.25, respectively. The minimum target
dose requirement was 95% of the prescribed dose in 98% of the PTVs. Furthermore, besides
critical structures such as brain and spinal cord tissue, parotid gland and swallowing related
organs (S1 Fig) were spared as much as possible [24].
PTV-based IMPT plans. PTV-based IMPT plans were constructed with identical OAR
objectives as IMRT plans, as described earlier [4]. However, as dose can be better conformed to
PTVs in proton therapy, OAR objectives could be set to lower doses or higher weights (S1
Table), whilst keeping adequate target coverage. Moreover, a PTV margin of 5 mm was used to
instead of 3.5 mm, because this could potentially account for both the range and setup errors in
proton plans. PTV-based optimization settings were kept identical for all field configurations
per patient, to prevent bias in the robustness analysis as function of field quantity.
Minimax IMPT plans. Minimax optimization aims to create robust IMPT plans by incor-
porating robustness into the optimization process [22]. Hereby, CTVs are targeted instead of
PTVs. Minimax IMPT plans were constructed with identical OAR objectives as for PTV-based
IMPT plans in all 5 field configurations, but again they could be set to lower doses or weights.
Since these plans target the CTV instead of PTV, all related objectives were replaced. The mini-
mum CTV dose requirements were increased by approximately 1.5–2 Gy. This was necessary
to achieve similar coverage of the CTV in minimax IMPT plans compared to PTV-based
IMRT and IMPT plans in the nominal situation. Potential errors were taken into account by
simulating different error scenarios. Range errors were simulated by proportionally changing
CT values by ± 3% [9,26]. Setup errors were incorporated by rigidly shifting the isocenter of
the beams in six isotropic orthogonal directions. To mimic the PTV margin of 3.5 mm, a dis-
placement of 3.5 mm was used as a magnitude of systematic setup errors for the robustness set-
tings. The simulated error scenarios included combinations of range and setup scenarios and
result in 21 error scenarios. Robustness is incorporated in the plans by optimizing the maxi-
mum objective function value of error scenarios including target and OARs objectives in these
error scenarios. To avoid convergence problems due to discontinuity of the gradient of the
objective function, the values of the other (not worst case) error scenarios are included with
small weights [27].
Evaluation of robustness. To evaluate plans for robustness, multiple possible range and
setup error combinations were simulated to investigate large variability of error scenarios in
patients. No anatomic deformation were included in our analysis. Range errors are simulated
by proportionally changing CT intensity values (+/-3%).The effect of setup errors was assessed
Table 2. Field configurations used for IMPT and IMRT plans.
Type Gantry angles (degree)
2F-IMPT 50° 310°
3F-IMPT 50° 310° 180°
5F-IMPT 50° 310° 115° 180° 245°
7F-IMPT 0° 50° 100° 150° 210° 260° 310°
7F-IMRT 0° 50° 100° 150° 210° 260° 310°
The IMPT conﬁgurations were applied for both PTV-based and minimax optimization. Gantry angles according to IEC 61217.
doi:10.1371/journal.pone.0152477.t002
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by shifting the isocenter isotropically in 26 directions on the radius of a sphere with a radius of
3.5 mm. It should be noted that in the evaluation of robustness more shifts were considered
than in the minimax optimization, where only 6 non-diagonal shifts were considered. The
robustness criterion is only met if none of all error scenarios causes under-dosage to the CTV.
For all 10 patients, the combined systematic setup and range errors ultimately resulted in
6240 and 260 perturbed dose distributions of IMPT and IMRT plans, respectively. These were
all compared to their corresponding planned, i.e. nominal dose distribution.
Evaluation measures
To meet the robustness criterion, CTVs were tested to receive acceptable target coverage in all
perturbed dose distributions. CTV coverage was acceptable if the dose that 98% of the volume
(D98) received was at least 95% of the prescribed dose (CTV70: D98>66.5 Gy; CTV54.25:
D98>51.5 Gy). Furthermore, target homogeneity (D5– D95) and hotspots (D2 and D5) were
considered.
To estimate the clinical benefit of using minimax IMPT in comparison to conventional
IMRT, Normal Tissue Complication Probability (NTCP) models for xerostomia and dysphagia
were used. The risk of xerostomia was estimated using the model described by Houweling et al.
[28]. In that study, xerostomia was defined as a minimal reduction in salivary flow (ml/min) to
25% of baseline level. For dysphagia, a multivariate regression NTCP model was used to esti-
mate grade 2–4 RTOG swallowing dysfunction 6 months after RT [29]. Both mean doses of
supraglottic larynx and superior pharyngeal constrictor muscle were individual input variables
for this model. Additionally, NTCP values of IMRT and minimax IMPT were compared in the
worst case error scenario.
Results
Nominal CTV coverage
In the nominal (non-error) scenarios, all CTVs were adequately covered in all PTV-based
plans and minimax plans. Average nominal CTV D98 of all patients and field configurations
were comparable for all investigated modalities (Table 3). Nominal target dose homogeneity
was comparable in IMRT and minimax IMPT plans and somewhat more homogeneous in
PTV-based IMPT plans (Table 3). The lower target dose homogeneity in nominal scenario
minimax IMPT plans was primarily due to a D5 increase for CTV70. However, no objectionable
hotspots were created in CTV70 in plans with more than 2 fields (D5< 73.6 Gy and D2<74.2
Gy in all patients). In error scenarios, PTV-based plans became more inhomogeneous com-
pared to IMRT and minimax IMPT. In minimax plans with 2 fields the maximum dose was
generally higher (D5< 73.9 Gy and D2<75.4 Gy). Maximum dose was observed in CTV70.
Plan robustness for target coverage
As expected, all IMRT plans met the robustness criterion, as minimal perturbed D98’s (D
min
98 ) of
all patients remained above the threshold of the robustness criterion in the presence of system-
atic errors (Fig 1A and 1C). The same holds true for minimax IMPT plans for all ﬁeld conﬁgu-
rations (Fig 1B and 1D). Average perturbed Dmin98 ’s of minimax and IMRT were comparable
(Table 3). In contrast, a large fraction of the perturbed Dmin98 for PTV-based IMPT plans failed
to meet the criterion. Acceptable target coverage of CTV70 and CTV54.25 was only ensured in 4
and 9 out of 40 plans, respectively. Moreover, for both CTVs, this was only in 1 out of 40 plans.
This corresponds to Dmin98 averages that were below the robustness criterion (Table 3). Insufﬁ-
cient robust PTV-based plans were seen in patients with HNC in all included anatomic subsites
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as listed in Table 1. Moreover, visual evaluation of the perturbed dose distributions showed
centralized cold spots in the CTV70 (Fig 2). Additionally, target dose homogeneity was more
stable in minimax than in PTV-based IMPT plans, as the perturbed homogeneity values
(Dmax5  Dmin95 ) were lower in minimax plans.
Furthermore, whereas increasing field numbers did not have much effect on plan robustness
in minimax plans, in PTV-based IMPT plans it appeared to have a somewhat a negative effect
on CTV54.25 coverage (Fig 1).
Benefit of minimax IMPT compared to IMRT
Comparing minimax IMPT to IMRT, there is a potential clinical benefit in terms of estimated
xerostomia and dysphagia NTCP values in all patients. However the magnitude of this benefit
varied among the individual HNC patients included in this study (Fig 3). Seven patients had
relatively large estimated improvements (ΔNTCP) with 5 field configurations. These patients
had a reduction of 10% for at least one of the evaluated complication probabilities and more
than 15% reduction of xerostomia and dysphagia NTCP values together. The summation of
NTCP of the individual patients are depicted in Fig 3. On average, NTCP reductions were
17.0% (95% CI; 13.0–21.1) for xerostomia and 8.1% (95% CI; 4.9–11.2) for dysphagia in these 7
patients.
The remaining 3 patients had average estimated reductions of 6.5% (95% CI; 4.2–8.8) for
xerostomia and 5.0% (95% CI; 1.2–8.8) for dysphagia. The NTCP values for xerostomia were
already low with IMRT in the two patients with laryngeal cancer and the patient with a T1N0
oropharyngeal cancer. Therefore, the absolute reduction of these values remained relatively
small.
The use of a 5-field instead of a 3-field configuration resulted in lower NTCP values in all
patients (Fig 3). It can be seen from Fig 4 that increasing the number of field improves the spar-
ing of healthy tissue, but that the benefit does not increase linearly. In other words, the esti-
mated benefit in terms of ΔNTCP still improves going from 5 to 7 fields, but not in the same
magnitude going from 2 to 3 or 3 to 5 fields.
Estimated NTCP reductions in the worst case scenarios of minimax IMPT compared to
IMRT for xerostomia and dysphagia were 17.1% (95% CI; 11.4–22.7) and 8.2% (95% CI; 6.1–
10.4) in the most favorable 7 patients, respectively. These reductions were very comparable to
those in the nominal scenario. The patient individual NTCP differences of IMRT, 3 field and 5
field minimax IMPT plans are also comparable in both worst and best case error scenarios,
which is depicted by error bars in Fig 3.
Table 3. Average CTV coverages and homogeneities per modality of all included plans.
Target Modality Nominal D98 Perturbed Dmin98 Nominal D5 − D95 Perturbed D
max
5  Dmin95
IMRT 68.9± 0.5 67.7± 0.8 3.3± 0.9 4.8± 0.7
CTV70 PTV-based IMPT 68.6± 0.4 64.4± 2.4 2.4± 0.5 7.4± 2.3
Minimax IMPT 68.5± 0.2 67.5± 0.5 4.2± 0.4 5.8± 0.6
IMRT 54.0± 0.8 53.2± 0.8 17.2± 1.0* 18.5± 0.9*
CTV54.25 PTV-based IMPT 53.5± 0.8 50.5± 1.4 16.9± 1.0* 20.8± 1.7*
Minimax IMPT 53.7± 0.6 52.7± 0.3 17.7± 0.9* 19.1± 0.8*
Values are in Gy and averaged over all patients and (2,3,5,7) ﬁeld conﬁgurations for the IMPT plans with their standard deviation (±).
*These values were obtained for CTV54.25 that contains CTV70. These values are not corrected for the simultaneous integrated boost.
Abbreviation: D98, dose that 98% of the CTV minimally receives; nominal, planned; perturbed, modeled with range and setup errors
doi:10.1371/journal.pone.0152477.t003
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Fig 1. Robustness performance of PTV andminimax optimization. Nominal D98 (blue) and worst-case scenario D
min
98 (red) of PTV-based (a,c) and
minimax IMPT plans (b,d) for CTV70 (a-b) and CTV54.25 (c-d). Solid lines connect the averages and boxplots represent the distribution of these parameters of
all patients per plan type. The horizontal blue lines represent the CTV dose criterion that marks 95% of the prescribed dose (66.5 Gy and 51.5 Gy).
doi:10.1371/journal.pone.0152477.g001
Estimated Benefit of Robust IMPT in HNC Patients
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Discussion
Our results demonstrate that selected HNC patients can benefit greatly from robust optimized
IMPT compared to IMRT in terms of estimated xerostomia and dysphagia NTCP values.
Moreover, our study showed that minimax optimization for IMPT is comparably robust for
systematic setup and range errors as the commonly applied PTV concept for IMRT. The mini-
max IMPT plans had adequate target coverage (D98> 95% of prescribed dose) of the CTVs in
all 3120 simulated error scenarios of these plans. Additionally, the NTCP benefit of IMPT to
IMRT remained similar in worst-case error scenarios, indicating that the investigated OARs
are not more sensitive to errors with IMPT.
In contrast, the PTV concept for IMPT showed poor robustness performance in HNC
patients, as acceptable target coverage in presence of errors was only obtained in 1 of 40 PTV-
based IMPT plans. Since enlarging the PTV margin to 5 mm could not prevent coldspots in
the border and center of CTVs, a margin concept seems inadequate for IMPT. These PTV
Fig 2. Example robustness performance in nominal and error scenario.Dose distributions of IMRT (a,d), PTV-based IMPT (b,e) and minimax optimized
IMPT plans (c,f) in nominal (a-c) and an error scenario (d-f) with a setup error of x = 0.25;y = 0;z = 0.25cm and a range error of 3%. Both CTV70 (blue lines)
and CTV54.25 (black lines) are shown in all dose distributions. IMPT plans were configured with 3 fields.
doi:10.1371/journal.pone.0152477.g002
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robustness results complement previous studies, indicating unfavorable use of the PTV concept
for IMPT [14,15,17]. However, the drastically poor robust performance of it that can be seen
from our result has to our knowledge never been shown to such an extent in HNC. This perfor-
mance was not improved by the use of different field configurations.
Although IMRT and minimax IMPT are comparable in terms of robustness, they are gener-
ally not comparable in terms of estimated NTCP values. Most of the patients included in this
Fig 3. Estimated normal tissue complication probabilities (NTCP).NTCP values of xerostomia (upper) and dysphagia (lower) are shown per patient for
IMRT (blue), 3-field minimax IMPT (gray) and 5-field minimax IMPT (green). ΔNTCP values comparing IMRT and 3 (upper table) or 5 fields (lower table) of
xerostomia and dysphagia are shown for every patients. A summation of these ΔNTCP are also given, and patients are sorted accordingly. Error bars
indicate NTCP values in worst and best case error scenarios.
doi:10.1371/journal.pone.0152477.g003
Fig 4. NTCP benefit of IMPT with different field configurations compared to IMRT. ΔNTCP and 95% confidence interval are given as a function of
number of minimax-optimized IMPT fields for xerostomia (left), dysphagia (right), for all patients (upper) and the 7 patients with combined NTCP reduction
larger than 15% (lower).
doi:10.1371/journal.pone.0152477.g004
Estimated Benefit of Robust IMPT in HNC Patients
PLOS ONE | DOI:10.1371/journal.pone.0152477 March 31, 2016 10 / 14
study could benefit greatly from IMPT, because of the relatively large NTCP changes. However,
this was not the case for all HNC patients. This argues for a careful selection procedure of
HNC patients that benefit from IMPT. Therefore, we consider individualized analysis to be
essential for the selection of HNC patients for proton therapy [30]. Although the threshold of
>15% combined xerostomia and dysphagia NTCP reduction to select the best HNC patients
was arbitrarily chosen, we believe that through such a method patients can be selected that can
have the most benefit of proton therapy [31]. It is noteworthy that use of different NTCP mod-
els may result in different estimated benefits. Current NTCP models are developed on patient
populations that are radiated with IMRT and they may be different when dose was delivered
with IMPT.
The estimated clinical benefit of IMPT that was shown by the studies that compared IMRT
and PTV-based IMPT plans [5,32] could have potentially been greater by using robust optimi-
zation instead of PTV-based IMPT plans. This was shown by the study of Stuschke et al. [23];
robust IMPT plan optimization may lead to a decrease in dose to body volume and OARs (ipsi-
lateral temporal lobe, cerebellum and brainstem) in HNC patients. Our findings comple-
mented this, but were kept outside the descriptive scope of this study.
Increasing the number of field directions did not significantly improve robustness for PTV-
based IMPT, which is in line with findings of Kraan et al. [17]. In fact, increasing field numbers
resulted in fewer patients with acceptable perturbed CTV54.25 coverage. This is probably due to
the increased conformity of dose to the target volume. Minimax IMPT plans did not show spe-
cific field dependency of the plan robustness considering both target volumes. Instead, a rela-
tionship between increasing field number and a decrease in mean dose to OARs was observed,
which also translated to reduced NTCP estimates. Especially increasing two to three field num-
bers lowered the dose to OARs substantially, which was also seen by Hopfgartner et al. [18].
We aimed at a realistic choice of setup and range errors in the robust optimization and eval-
uation in this study but it can still be argued that they are too small or too large. Techniques
like cone beam CT and dual energy CT are not commonly available in proton clinics but can
be expected to be standard practice in the near future [33]. In this work, the choice of setup
and range errors in robust planning is therefore somewhat arbitrary and is subject to change
depending on development of available imaging and verification techniques at proton treat-
ment clinics. Secondly, the PTV margin for the proton plans was enlarged with 1.5 mm, in an
attempt to account for the range error, resulting from CT inaccuracies. Although this is also
arbitrarily chosen, we believe that enlargement of the PTV margin would not improve the
results sufficiently, as in IMPT plans errors will still occur in the center of the CTV. Next to the
CTV central located errors, also the errors are often located at the border of the target volume.
Therefore, we believe that reducing the PTV will influence the robustness even more.
Even though both IMRT and minimax IMPT modalities are robust, not including robust
optimization for IMRT plans and by using a 10 mm leaf width instead of 5 mmmight have
overestimated the benefit in terms of NTCP values of IMPT somewhat [34]. Nevertheless, we
expect that robust optimization for IMRT will not eliminate the estimated significance of
IMPT for well selected HNC patients, because also the minimax IMPT plans could be
improved. In contrast to IMRT, the optimization time of minimax IMPT is long (~ 1 hour),
making it impracticable to iterate the optimization procedure to find the optimal plan. Further-
more, not included in the robustness optimization and evaluating are random setup errors,
which blur dose distributions by changing inter-fractionally. In the PTV concept the random
errors are taken into account by enlarging the margin slightly [35], we expect that the same can
apply for using a slightly enlarged setup error as input for the robust optimization. Further
research is necessary to investigate if indeed the impact of random errors for IMPT is similar to
that for IMRT in HNC patients. The same applies to rotational displacements and anatomic
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deformations. We do believe that some of these non-rigid displacement errors could partly be
accounted for by robust optimization, since fixation techniques (thermoplastic mask and head-
rest) ensure a minimum variation in neck tilt and these errors may be mimicked by rigid shifts
that are simulated by the robust optimization. However, some anatomic changes may require a
different robustness approach, such as deformation modeling within robust optimization or
online adaptive treatment [17].
Conclusion
Minimax optimized IMPT and IMRT plans were comparably robust in the presence of all sim-
ulated combinations of systematic range and setup errors, but PTV-based IMPT plans were
not. The estimated clinical benefit in terms of adequate target coverage and minimal NTCP of
minimax IMPT was in all HNC larger than IMRT, but in 7 especially substantial. The NTCP
benefit of IMPT compared to IMRT remained similar in worst-case error scenarios. Increasing
field numbers did not contribute to plan robustness, but contributed to organ sparing. There-
fore, we conclude that minimax IMPT with a sufficient number of fields offers the opportunity
to create robust plans with increased estimated clinical benefit compared to IMRT.
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